{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:09:41Z","timestamp":1787062181287,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Intravesical BCG instillation after bladder tumor resection is the standard treatment for non-muscle invasive bladder cancer; however, it is not always effective and frequently has undesirable side effects. Therefore, new strategies that improve the clinical management of patients are urgently needed. This study aimed to comprehensively evaluate the bladder tumor immune microenvironment profile after intravesical treatment with a panel of mycobacteria with variation in their cell envelope composition and its impact on survival using an orthotopic murine model to identify more effective and safer therapeutic strategies. tumor-bearing mice were intravesically treated with a panel of BCG and\n M. brumae<\/jats:italic>\n cultured under different conditions. Untreated tumor-bearing mice and healthy mice were also included as controls. After mycobacterial treatments, the infiltrating immune cell populations in the bladder were analysed by flow cytometry. We provide evidence that mycobacterial treatment triggered a strong immune infiltration into the bladder, with BCG inducing higher global absolute infiltration than\n M. brumae<\/jats:italic>\n . The induced global immune microenvironment was strikingly different between the two mycobacterial species, affecting both innate and adaptive immunity. Compared with\n M. brumae<\/jats:italic>\n , BCG treated mice exhibited a more robust infiltration of CD4\n +<\/jats:sup>\n and CD8\n +<\/jats:sup>\n T-cells skewed toward an effector memory phenotype, with higher frequencies of NKT cells, neutrophils\/gMDSCs and monocytes, especially the inflammatory subset, and higher CD4\n +<\/jats:sup>\n T\n EM<\/jats:sub>\n \/CD4\n +<\/jats:sup>\n T\n reg<\/jats:sub>\n and CD8\n +<\/jats:sup>\n T\n EM<\/jats:sub>\n \/CD4\n +<\/jats:sup>\n T\n reg<\/jats:sub>\n ratios. Conversely,\n M. brumae<\/jats:italic>\n treatment triggered higher proportions of total activated immune cells and activated CD4\n +<\/jats:sup>\n and CD8\n +<\/jats:sup>\n T\n EM<\/jats:sub>\n cells and lower ratios of CD4\n +<\/jats:sup>\n T\n EM<\/jats:sub>\n cells\/CD4\n +<\/jats:sup>\n T\n regs<\/jats:sub>\n , CD8\n +<\/jats:sup>\n T\n EM<\/jats:sub>\n cells\/CD4\n +<\/jats:sup>\n T\n regs<\/jats:sub>\n and inflammatory\/reparative monocytes. Notably, the mycobacterial cell envelope composition in\n M. brumae<\/jats:italic>\n had a strong impact on the immune microenvironment, shaping the B and myeloid cell compartment and T-cell maturation profile and thus improving survival. Overall, we demonstrate that the bladder immune microenvironment induced by mycobacterial treatment is species specific and shaped by mycobacterial cell envelope composition. Therefore, the global bladder immune microenvironment can be remodelled, improving the quality of infiltrating immune cells, the balance between inflammatory and regulatory\/suppressive responses and increasing survival.\n <\/jats:p>","DOI":"10.3389\/fimmu.2022.993401","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T07:32:24Z","timestamp":1665473544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Remodeling the bladder tumor immune microenvironment by mycobacterial species with changes in their cell envelope composition"],"prefix":"10.3389","volume":"13","author":[{"given":"Jordi","family":"Senserrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra\u00a0","family":"Guallar-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Gomez-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Juli\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200211000-00016","article-title":"Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/00005392-200202000-00011","article-title":"Superficial bladder carcinoma treated with bacillus calmette-guerin","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2082869","article-title":"Emerging treatment landscape of non-muscle invasive bladder cancer","volume":"22","author":"Valenza","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"175024","DOI":"10.1016\/j.ejphar.2022.175024","article-title":"Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions","volume":"926","author":"Li","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of bacillus calmette-gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: Results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus calmette-gu\u00e9rin (BCG) therapy for bladder cancer: An update","volume":"9","author":"Guallar-Garrido","year":"2020","journal-title":"ImmunoTargets Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/vaccines8020198","article-title":"Mycolicibacterium brumae is a safe and non-toxic immunomodulatory agent for cancer treatment","volume":"8","author":"Bach-Griera","year":"2020","journal-title":"Vaccines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.juro.2015.07.011","article-title":"\u03b3 irradiated mycobacteria enhance survival in bladder tumor bearing mice although less efficaciously than live mycobacteria","volume":"195","author":"Noguera-Ortega","year":"2016","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15102","DOI":"10.1038\/s41598-018-33253-w","article-title":"Intravesical mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice","volume":"8","author":"Noguera-Ortega","year":"2018","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euf.2015.03.003","article-title":"Nonpathogenic mycobacterium brumae inhibits bladder cancer growth In vitro, ex vivo, and In vivo","volume":"2","author":"Noguera-Ortega","year":"2016","journal-title":"Eur Urol Focus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer-a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1602460","DOI":"10.1080\/2162402X.2019.1602460","article-title":"Combined assessment of peritumoral Th1\/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC","volume":"8","author":"Mart\u00ednez","year":"2019","journal-title":"Oncoimmunology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00175","article-title":"Modifying the non-muscle invasive bladder cancer immune microenvironment for optimal therapeutic response","volume":"10","author":"Annels","year":"2020","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-\u03b3 signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B20","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2051845","article-title":"Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-gamma\/IL-17 release in bladder cancer treatment","volume":"11","author":"Guallar-Garrido","year":"2022","journal-title":"OncoImmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/microorganisms8050734","article-title":"Each mycobacterium requires a specific culture medium composition for triggering an optimized immunomodulatory and antitumoral effect","volume":"8","author":"Guallar-Garrido","year":"2020","journal-title":"Microorganisms"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.731947","article-title":"Regulatory T cells in autoimmunity and cancer: A duplicitous lifestyle","volume":"12","author":"Hatzioannou","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2630","article-title":"A conserved human T cell population targets mycobacterial antigens presented by CD1b","volume":"14","author":"Van Rhijn","year":"2013","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Effects of local bacillus calmette-guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"B\u00f6hle","year":"1990","journal-title":"J Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2001.02394.x","article-title":"Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus calmette-gu\u00e9rin treatment","volume":"88","author":"Saint","year":"2001","journal-title":"BJU"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00194","article-title":"CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function","volume":"8","author":"Takeuchi","year":"2017","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204745","article-title":"Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens","volume":"13","author":"Murai","year":"2018","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ni1179","article-title":"A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0811556106","article-title":"Heterogeneity of natural Foxp3 + T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity","volume":"106","author":"Komatsu","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01270","article-title":"Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications","volume":"9","author":"Joseph","year":"2019","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/sji.12830","article-title":"Tumor-associated b cells in urothelial urinary bladder cancer","volume":"91","author":"Zirakzadeh","year":"2020","journal-title":"Scand J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2021.678127","article-title":"B cell orchestration of anti-tumor immune responses: A matter of cell localization and communication","volume":"9","author":"Kinker","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117309","article-title":"Requirement for CD1d expression by b cells to stimulate NKT cell\u2013enhanced antibody production","volume":"111","author":"Lang","year":"2008","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12909","article-title":"Both b-1a and b-1b cells exposed to mycobacterium tuberculosis lipids differentiate into IgM antibody-secreting cells","volume":"154","author":"Ordo\u00f1ez","year":"2018","journal-title":"Immunology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4569","article-title":"Tumor microenvironment b cells increase bladder cancer metastasis via modulation of the IL-8\/androgen receptor (AR)\/MMPs signals","volume":"6","author":"Ou","year":"2015","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00899","article-title":"The role of tumor-associated myeloid cells in modulating cancer therapy","volume":"10","author":"Neophytou","year":"2020","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.3390\/cancers13184712","article-title":"Tumor-associated macrophages in bladder cancer: Biological role, impact on therapeutic response and perspectives for immunotherapy","volume":"13","author":"Leblond","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu Rev Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01371","article-title":"Myeloid-derived suppressor cells in tumors: From mechanisms to antigen specificity and microenvironmental regulation","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.02100","article-title":"Plasticity in pro- and anti-tumor activity of neutrophils: Shifting the balance","volume":"11","author":"Furumaya","year":"2020","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.11.031","article-title":"Role of neutrophils in BCG immunotherapy for bladder cancer","volume":"26","author":"Simons","year":"2008","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus calmette-gu\u00e9rin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086660","article-title":"The monocyte to macrophage transition in the murine sterile wound","volume":"9","author":"Crane","year":"2014","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.993401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T07:32:32Z","timestamp":1665473552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.993401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2022.993401"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.993401","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"article-number":"993401"}}